Implementing New Data and Evolving Standards in Metastatic Triple-Negative Breast Cancer

STATEMENT OF NEED

Breast cancer accounts for approximately 30% of cancer diagnoses among women in the United States and is the second-leading cause of cancer death in this population. About 20% of patients have invasive triple-negative breast cancer (TNBC), which is defined as having estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) negativity. Whereas therapies targeting these receptors have demonstrated efficacy in other breast cancer subtypes, patients with TNBC are instead typically treated with standard chemotherapy, which does not always prove to be effective. While there have been advances with adjuvant chemotherapy, patients with TNBC still have a poorer prognosis than do patients who present with HR-positive or HER2-positive disease; for those with metastatic TNBC, the estimated median overall survival is only 13 months.

TARGET AUDIENCE

Medical oncologists, surgical oncologists, radiation oncologists, oncology advanced practitioners, oncology nurses, and other health care professionals involved in the treatment of patients with triple-negative breast cancer (TNBC).

LEARNING OBJECTIVES

Upon completion of this activity, participants should be able to:

1. Evaluate clinical and molecular factors that can inform personalized care plans for patients with TNBC
2. Explain guideline recommendations for genetic risk evaluation in patients with TNBC
3. Differentiate emerging efficacy and safety data on novel therapies for metastatic TNBC